AIM ImmunoTech Inc. 8-K

What Happened
AIM ImmunoTech, Inc. (AIM) filed a Form 8‑K on June 4, 2026 to disclose an on‑demand video presentation describing previously published pre‑clinical findings on its lead drug candidate Ampligen® (rintatolimod) and its potential role as a prophylactic and/or early‑onset antiviral treatment for Ebola virus disease (EVD). The company made the Virtual Investor “What This Means” segment available at https://virtualinvestorco.com/aim and posted an investor slide deck on its site at https://aimimmuno.com/presentations. A press release and the slide deck were furnished as Exhibits 99.1 and 99.2 to the filing.

Key Details

• Filing date: June 4, 2026 (Form 8‑K, Item 7.01 Regulation FD Disclosure).
• Topic: Pre‑clinical data on Ampligen® (rintatolimod) for prophylactic and/or early antiviral use against Ebola virus disease.
• Materials posted: on‑demand video presentation (VirtualInvestorCo link) and investor presentation slide deck (AIM website); press release and slide deck included as Exhibits 99.1 and 99.2.
• Regulation FD: information was broadly disclosed via the 8‑K and public web postings.

Why It Matters
This disclosure updates investors on AIM’s research direction and publicly shares pre‑clinical data for a potential new indication of Ampligen. While the filing does not announce clinical trials, regulatory approvals, or financial results, the public dissemination of these research materials could affect investor perception of AIM’s pipeline development and strategic focus. The use of a Regulation FD filing ensures the information was shared broadly and in compliance with disclosure rules.